# Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

> **NCT05153330** · PHASE1 · TERMINATED · sponsor: **Biomea Fusion Inc.** · enrollment: 55 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Acute Mixed-Phenotype Leukemia
- Cancer
- Refractory
- Progression
- Diffuse Large B Cell Lymphoma
- Multiple Myeloma
- Lymphoma
- Lymphoma, Non-Hodgkin
- Myeloma, Plasma-Cell
- Myelomatosis
- Plasma Cell Myeloma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** BMF-219

## Key facts

- **NCT ID:** NCT05153330
- **Lead sponsor:** Biomea Fusion Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-24
- **Primary completion:** 2025-02-13
- **Final completion:** 2025-05-02
- **Target enrollment:** 55 (ACTUAL)
- **Why stopped:** Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05153330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05153330, "Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05153330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*